Preclinical models to evaluate new therapies for blood cancer
Blood cancer is a cancer that affects the production and function of blood cells. The most common types of blood cancer include leukemia, lymphoma, and multiple myeloma. These cancers can affect the cells that make up the blood, such as white blood cells, red blood cells, and platelets. Traditionally treated with doxorubicin, many new treatments have now become available, including many immuno-therapies.
Oncodesign Services supports you with in vitro and in vivo models established for blood cancer
For developers of blood cancer therapies, Oncodesign Services offers these kinds of support:
- In vitro screening: flow/FACS-based assays using heme CDX models. Survival, activation, differentiation.
- In vivo modeling: CDX and PDX modeling in immune compromised (typically SCID) and humanized mice.
- Biomarker analysis: flow/FACS and cytokine analysis, including GLP-grade sample analysis.
- Biodistribution and clearance: Radiotag your therapy and detect with imaging to confirm good half-life.